BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

776 related articles for article (PubMed ID: 27320035)

  • 1. Is the type of gonadotropin-releasing hormone suppression protocol for ovarian hyperstimulation associated with ectopic pregnancy in fresh autologous cycles for in vitro fertilization?
    Londra L; Moreau C; Strobino D; Bhasin A; Zhao Y
    Fertil Steril; 2016 Sep; 106(3):666-72. PubMed ID: 27320035
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of live-birth defects after luteal-phase ovarian stimulation vs. conventional ovarian stimulation for in vitro fertilization and vitrified embryo transfer cycles.
    Chen H; Wang Y; Lyu Q; Ai A; Fu Y; Tian H; Cai R; Hong Q; Chen Q; Shoham Z; Kuang Y
    Fertil Steril; 2015 May; 103(5):1194-1201.e2. PubMed ID: 25813280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential impact of controlled ovarian hyperstimulation on live birth rate in fresh versus frozen embryo transfer cycles: a Society for Assisted Reproductive Technology Clinic Outcome System study.
    Gerber RS; Fazzari M; Kappy M; Cohen A; Galperin S; Lieman H; Jindal S; Buyuk E
    Fertil Steril; 2020 Dec; 114(6):1225-1231. PubMed ID: 33012553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Consistent high clinical pregnancy rates and low ovarian hyperstimulation syndrome rates in high-risk patients after GnRH agonist triggering and modified luteal support: a retrospective multicentre study.
    Iliodromiti S; Blockeel C; Tremellen KP; Fleming R; Tournaye H; Humaidan P; Nelson SM
    Hum Reprod; 2013 Sep; 28(9):2529-36. PubMed ID: 23873146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study.
    Engmann L; DiLuigi A; Schmidt D; Nulsen J; Maier D; Benadiva C
    Fertil Steril; 2008 Jan; 89(1):84-91. PubMed ID: 17462639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intranasal gonadotropin-releasing hormone agonist (GnRHa) for luteal-phase support following GnRHa triggering, a novel approach to avoid ovarian hyperstimulation syndrome in high responders.
    Bar-Hava I; Mizrachi Y; Karfunkel-Doron D; Omer Y; Sheena L; Carmon N; Ben-David G
    Fertil Steril; 2016 Aug; 106(2):330-3. PubMed ID: 27114332
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk factors for ectopic pregnancy in assisted reproductive technology: a 6-year, single-center study.
    Bu Z; Xiong Y; Wang K; Sun Y
    Fertil Steril; 2016 Jul; 106(1):90-94. PubMed ID: 27001382
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of clinical outcomes between the depot gonadotrophin-releasing hormone agonist protocol and gonadotrophin-releasing hormone antagonist protocol in normal ovarian responders.
    Xia M; Zheng J
    BMC Pregnancy Childbirth; 2021 May; 21(1):372. PubMed ID: 33975553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GnRH agonist and GnRH antagonist protocols: comparison of outcomes among good-prognosis patients using national surveillance data.
    Grow D; Kawwass JF; Kulkarni AD; Durant T; Jamieson DJ; Macaluso M
    Reprod Biomed Online; 2014 Sep; 29(3):299-304. PubMed ID: 25043892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Triggering with human chorionic gonadotropin or a gonadotropin-releasing hormone agonist in gonadotropin-releasing hormone antagonist-treated oocyte donor cycles: findings of a large retrospective cohort study.
    Bodri D; Guillén JJ; Galindo A; Mataró D; Pujol A; Coll O
    Fertil Steril; 2009 Feb; 91(2):365-71. PubMed ID: 18367175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gonadotropin-releasing hormone agonist trigger in oocyte donors co-treated with a gonadotropin-releasing hormone antagonist: a dose-finding study.
    Vuong TN; Ho MT; Ha TD; Phung HT; Huynh GB; Humaidan P
    Fertil Steril; 2016 Feb; 105(2):356-63. PubMed ID: 26523330
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ectopic pregnancy after in vitro fertilization: differences between fresh and frozen-thawed cycles.
    Londra L; Moreau C; Strobino D; Garcia J; Zacur H; Zhao Y
    Fertil Steril; 2015 Jul; 104(1):110-8. PubMed ID: 25956363
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Comparison of GnRH antagonist fixed protocol and GnRH agonists long protocol in infertile patients with normal ovarian reserve function in their first in vitro fertilization-embryo transfer cycle].
    Yang S; Chen XN; Qiao J; Liu P; Li R; Chen GA; Ma CH
    Zhonghua Fu Chan Ke Za Zhi; 2012 Apr; 47(4):245-9. PubMed ID: 22781108
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessing the adequacy of gonadotropin-releasing hormone agonist leuprolide to trigger oocyte maturation and management of inadequate response.
    Chang FE; Beall SA; Cox JM; Richter KS; DeCherney AH; Levy MJ
    Fertil Steril; 2016 Oct; 106(5):1093-1100.e3. PubMed ID: 27341988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cycle day, estrogen level, and lead follicle size: analysis of 27,790 in vitro fertilization cycles to determine optimal start criteria for gonadotropin-releasing hormone antagonist.
    Lyttle Schumacher BM; Mersereau JE; Steiner AZ
    Fertil Steril; 2018 Apr; 109(4):633-637. PubMed ID: 29605403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is the effect of premature elevated progesterone augmented by human chorionic gonadotropin versus gonadotropin-releasing hormone agonist trigger?
    Connell MT; Patounakis G; Healy MW; DeCherney AH; Devine K; Widra E; Levy MJ; Hill MJ
    Fertil Steril; 2016 Sep; 106(3):584-589.e1. PubMed ID: 27178228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of luteal phase vaginal estradiol supplementation on the success of in vitro fertilization treatment: a prospective randomized study.
    Engmann L; DiLuigi A; Schmidt D; Benadiva C; Maier D; Nulsen J
    Fertil Steril; 2008 Mar; 89(3):554-61. PubMed ID: 17678651
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GnRH agonist trigger with intensive luteal phase support vs. human chorionic gonadotropin trigger in high responders: an observational study reporting pregnancy outcomes and incidence of ovarian hyperstimulation syndrome.
    Christopoulos G; Vlismas A; Carby A; Lavery S; Trew G
    Hum Fertil (Camb); 2016 Sep; 19(3):199-206. PubMed ID: 27662416
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pregnancy outcomes after controlled ovarian hyperstimulation in women with endometriosis-associated infertility: GnRH-agonist versus GnRH-antagonist.
    Kolanska K; Cohen J; Bendifallah S; Selleret L; Antoine JM; Chabbert-Buffet N; Darai E; d'Argent EM
    J Gynecol Obstet Hum Reprod; 2017 Nov; 46(9):681-686. PubMed ID: 28970135
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gonadotropin-releasing hormone analogue as sole luteal support in antagonist-based assisted reproductive technology cycles.
    Bar Hava I; Blueshtein M; Ganer Herman H; Omer Y; Ben David G
    Fertil Steril; 2017 Jan; 107(1):130-135.e1. PubMed ID: 28228316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.